

1 **SMOOTH protocol: A pilot randomised prospective intra-**
2 **patient single-blinded observational study for examining**
3 **the mechanistic basis of ablative fractional carbon dioxide**
4 **laser therapy in treating hypertrophic scarring**

5 Yung-Yi Chen^{1,2}¶*, Krupali M. Patel^{3,4}¶, Rizwana Imran^{3,4}¶, Tarek Hassouna^{3,4}, Ezekwe
6 Amirize^{3,4}, Abdulrazak Abdulsalam^{3,4}, Jonathan Bishop^{3,4}, Anita Slade^{3,5}, Maximina Ventura⁴,
7 Jeremy Yarrow⁶, Janet M. Lord^{1,2,3}, Yvonne Wilson^{1,7}, Naiem S. Moiemem^{1, 2, 3,4}

8

9 1 The Scar Free Foundation Centre for Conflict Wound Research, Queen Elizabeth Hospital
10 Birmingham, Birmingham, United Kingdom

11 2 Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United
12 Kingdom

13 3 National Institute for Health Research Surgical Reconstruction and Microbiology Research
14 Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United
15 Kingdom

16 4 Queen Elizabeth Hospital Birmingham, University Hospital Birmingham NHS Foundation
17 Trust, Birmingham, United Kingdom

18 5 Institute of Applied Health Research, University of Birmingham, Birmingham, United
19 Kingdom

20 6 Welsh Centre for Burns and Plastic Surgery Morriston Hospital, Swansea, United Kingdom

21 7 Birmingham Children's Hospital, Birmingham Women's and Children's NHS Foundation
22 Trust, Birmingham, United Kingdom

23

24 ¶ Shared first authorship

25 *Corresponding author: y.chen@bham.ac.uk (YC)

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **Abstract**

28 **Background:** Burn injuries are the fourth most common type of trauma and are associated
29 with substantial morbidity and mortality. The impact of burn injury is clinically significant as
30 burn injuries often give rise to exuberant scarring. Hypertrophic scarring (HTS) is a particular
31 concern as up to 70% of burns patients develop HTS. Laser therapy is used for treating HTS
32 and has shown positive clinical outcomes, although the mechanisms remain unclear limiting
33 approaches to improve its effectiveness. Emerging evidence has shown that fibroblasts and
34 senescent cells are important modifiers of scarring. This study aims to investigate the cellular
35 kinetics in HTS after laser therapy, with a focus on the association of scar reduction with the
36 presence of senescent cells.

37 **Methods:** We will conduct a multicentre, intra-patient, single-blinded, randomised
38 controlled longitudinal pilot study with parallel assignments to achieve this objective. 60
39 participants will be recruited to receive 3 interventional ablative fractional CO₂ laser treatments
40 over a 12-month period. Each participant will have two scars randomly allocated to receive
41 either laser treatment or standard care. Biopsies will be obtained from laser-treated, scarred-
42 no treatment and non-scarred tissues for immune-histological staining to investigate the
43 longitudinal kinetics of p16^{INK4A+}-senescent cells and fibroblast subpopulations (CD90⁺/Thy1⁺
44 and αSMA⁺). Combined subjective scar assessments including Modified Vancouver Scar
45 Scale, Patient and Observer Scar Assessment Scale and Brisbane Burn Scar Impact Profile;
46 and objective assessment tools including 3D-Vectra-H1 photography, DermaScan[®] Cortex,
47 Cutometer[®] and ColoriMeter[®]DSMIII will be used to evaluate clinical outcomes. These will
48 then be used to investigate the association between senescent cells and scar reduction after
49 laser therapy. This study will also collect blood samples to explore the systemic biomarkers
50 associated with the response to laser therapy.

51 **Discussion:** This study will provide an improved understanding of mechanisms potentially
52 mediating scar reduction with laser treatment, which will enable better designs of laser
53 treatment regimens for those living with HTS.

54 **Trial registration:** ClinicalTrials.gov: NCT04736251.

55 **Keywords:** Burns, Hypertrophic scarring, Laser therapy, Senescence, Fibroblasts.

56 **Introduction**

57 Burn injury is the fourth most common type of trauma after road traffic accidents, falls and
58 interpersonal intentional injury and is associated with substantial morbidity and mortality.
59 According to the World Health Organisation, burn injuries account for around 180,000 deaths
60 worldwide annually, with approximately 11 million people requiring medical attention each
61 year.(1) The cost of wound care in clinical practice over 24 months in the UK is estimated
62 around £16,924 per burn.(2) The impact of burn injuries is clinically significant as burn injuries
63 often give rise to exuberant scarring that results in permanent physical function loss and
64 psychological issues due to the stigma of disfigurement. These outcomes ultimately lead to
65 profound long-term effects on quality of life (QoL). Up to 90% of the patients who survive a
66 burn injury suffer from post-burn scarring.(3, 4) Among different types of scarring, hypertrophic
67 scarring is a particular concern in deep, full and partial thickness burn injuries and up to 70%
68 of patients develops hypertrophic scars (HTS) following burns.(5)

69 Burn care during the last 30 years has seen a step change in survival and this has been
70 paralleled by improved acute care and durable wound cover resulting in less deformity and
71 scarring. However, there remains an urgent need for improvements in post-burn scar
72 assessment, management and the treatment of historic scars. Gangemi et al in a
73 comprehensive review of 703 burn survivors' records identified the key risk factors for post-
74 burn hypertrophic scarring.(6) These factors included age, gender, dark skin, burn severity,
75 number of surgical procedures performed to achieve wound cover, burn location (neck and/or
76 upper limbs) and time to wound healing. How these factors influence the treatment of
77 established scars remains poorly understood.

78 **Treatments for post-burn HTS**

79 Post-burn HTS is typically treated non-invasively with the use of topical emollients, silicone
80 gel, compression garments or these modalities in various combinations. A survey of 19

81 paediatric burn services in the UK showed that 18 services routinely use pressure garments
82 for prevention of HTS following burn injury.(7) More recently, intra-lesional therapy using
83 steroids or anti-neoplastic drugs such as fluorouracil, bleomycin and interferon have come into
84 use.(8, 9) Other commonly used drugs include verapamil and botulinum toxin type-A, which
85 have been reported to be beneficial if injected either alone or in combination with steroids.(10)
86 Laser therapy for treating HTS is a relatively new concept started in the 1980s, being used
87 initially to treat port-wine stains and remove decorative tattooing.(11, 12) Although its use is
88 becoming more widespread for the reduction of established scars, its efficacy and mechanism
89 of action remain to be established. Three main methodological variants of laser therapy have
90 been developed over the years to treat specific aspects of established scars: Pulsed-dye
91 lasers, Q-switched Nd:YAG lasers and fractional lasers.(13) Pulsed-dye laser therapy was
92 used to reduce scar vascularity by inducing disruption of the targeted capillaries. This method
93 was also reported to reduce itch.(14) Nd:YAG lasers emit light in the infra-red range, typically
94 with a wavelength of 1064nm and have deeper tissue penetration.

95 Recently, twelve RCTs of laser therapy for the treatment of HTS, involving 592 patients, were
96 considered in a systematic review.(15) Although 11 of these trials reported a positive effect of
97 the therapy the review concluded there was insufficient evidence of the clinical effectiveness
98 of laser therapy. This was largely due to variations in the laser therapy used, the scar
99 assessment methods selected and inadequate study design. Currently there are 3 RCTs open
100 in Canada and one in the US, this promising new therapy thus remains to have its clinical
101 efficacy in scar management confirmed.

102 **Fractional carbon dioxide laser therapy**

103 Fractionated CO₂ laser therapy was introduced by Manstein et al in 2004 and essentially
104 bridges the gap between the ablative and non-ablative laser techniques.(16) Ablative laser
105 treatments work mainly on the epidermis and non-ablative treatments work solely on dermal
106 collagen, fractional laser treatment works at both the epidermal and dermal layers of the skin

107 making it suitable for treating several aspects of HTS. The CO₂ lasers have a wavelength of
108 10,600nm which can be heavily absorbed by water. One study has suggested that a CO₂ laser
109 pulsed at less than 1ms, can limit the residual thermal damage to 100-150µm layer of skin by
110 vaporizing tissue up to 20-30µm per pulse.(17, 18) It is thought that CO₂ lasers allow
111 immediate contraction of the ablative areas by denaturing the existing old collagen and
112 stimulate new collagen formation.(18, 19) However, whether this is all that laser therapy does
113 to achieve scar reduction seems unlikely and until we fully understand its mode of action this
114 will limit approaches to improve its efficacy.

115 The Lumenis UltraPulse Encore model with DeepFX™ head piece is an advanced fractional
116 CO₂ laser system with three modes to deliver its energy: ActiveFX™, DeepFX™ and
117 TotalFX™. The feature of DeepFX™ is that it focuses the laser's energy into a 0.12mm spot
118 size and allows for deep ablation of the tissue which can be useful for treating HTS resulting
119 from deep partial thickness burn injuries. The principle of the Lumenis UltraPulse Encore
120 DeepFX™ is in line with most of the CO₂ lasers in that it introduces a beam of laser energy
121 into the skin that generates an area of microscopic thermal injuries and allows the body to
122 create a more rapid wound healing process and promote extracellular remodelling.(17, 20) It
123 has been suggested that repeated treatments have continuous effects and facilitate scar
124 tissues to remodel to a more normal and smooth appearance.(21) Because of the versatile
125 and advanced features of this instrument, it will be used in this pilot study.

126 **Scar assessment tools**

127 To assess scar development over time, the use of reliable scar assessment tools is crucial.
128 Currently, subjective scar assessments such as Patient Observer Scar Assessment Scale
129 (POSAS), Vancouver Scar Scale (VSS) and Brisbane Burn Scar Impact Profile (BBSIP) have
130 been widely used in clinical practice. These assessments are in the form of questionnaires to
131 reflect patients' satisfaction as well as clinician's perspectives toward the scars. However,
132 these questionnaires only provide qualitative and/or semi-quantitative measures for post-burn

133 scar assessment (22, 23). With the recent introduction of objective scar assessment tools,
134 such as 3D-cameras (Eykona, Lifestar and Vectra H1), DSMII and DSMIII ColoriMeter[®],
135 Cutometer[®] and DermaScan[®] high frequency ultrasound, accurate and reproducible
136 evaluation of scars is made possible.(22) These quantitative tools measure different properties
137 of the scar. For example, DermaScan[®] measures scar thickness and density, DSMIII
138 ColoriMeter[®] quantifies colour, Cutometer[®] assesses skin elasticity and the 3D-camera allows
139 measuring the surface area and the volume of the scars. Contrary to subjective scar
140 assessments, these quantitative assessment scores do not reflect patients' satisfaction
141 towards scars. With patients' overall wellbeing in mind, to only report one area of the scar
142 property may not represent the whole picture of the scar recovery. Therefore, a standardised
143 scar assessment tool that incorporates objective scar assessment tools with the patient's
144 subjective satisfactory scoring systems would represent a more thorough and reliable
145 assessment. In this study, a combination of assessment tools will be used to assess the
146 clinical outcomes of the laser treatment.

147 **Cellular mechanisms**

148 The cellular and molecular mechanisms behind laser therapy remains under researched.
149 What is known so far is that dermal fibroblasts have been identified as the major player in skin
150 wound healing (24) and it is likely that they will also be important in the response to laser
151 therapy. One potential mechanism is the induction of cell senescence in response to the
152 damage inflicted by the laser. Despite senescent cells playing a negative role in ageing (25)
153 they also have positive effects. In recent years the beneficial role of cellular senescence in
154 wound healing has been revealed. A study using a p16-3MR-transgenic mouse model in which
155 senescent cells were deleted as they arise revealed slower wound healing. (26) The positive
156 effects of senescent cells are likely mediated through their secretome, the senescence-
157 associated secretory phenotype (SASP), which contains a range of pro-inflammatory
158 cytokines, proteases and growth factors. The senescent cells appeared very early in response

159 to a cutaneous injury, where they accelerate wound closure by inducing myofibroblast
160 differentiation through the secretion of platelet-derived growth factor AA (PDGF-AA).(26)
161 Another study provided evidence for the crosstalk between senescent fibroblasts and
162 keratinocytes in human skin through a novel SASP factor contained in extracellular vehicles,
163 namely miR-23a-3p which accelerates wound healing *in vitro*.(27) Given the central role of
164 dermal fibroblasts and the beneficial role of senescent cells in promoting wound healing, it is
165 likely the two cell types also participate in the tissue remodelling process post-laser therapy.

166 **Study objectives and aims**

167 The study's primary objective is to assess the kinetics of the response to ablative fractional
168 CO₂ laser therapy in HTS with respect to the cell types present in the treated skin. We will
169 examine the presence of p16INK4A and γ H2AX positive senescent cells, and CD90/Thy1⁺-
170 and α SMA⁺-fibroblast subpopulations together with the combined subjective and objective
171 scar assessments to measure the association between induction of senescent cells and scar
172 reduction after laser treatment.

173 We suggest that improved understanding of the mechanisms that mediate scar reduction with
174 laser treatment, will enable better design of laser treatment regimens, and thus benefit those
175 living with HTS.

176 **Materials and methods**

177 **Study design**

178 SMOOTH (A prospective intra-patient **S**ingle-blinded randomised trial to examine the
179 **M**echanistic basis of fracti**O**nal ablative carb**O**n dioxide laser **T**herapy in the treating adult
180 burns and/or trauma patients with **H**ypertrophic scarring) is a multicentre, intra-patient, single-
181 blinded randomised controlled longitudinal pilot observational study with parallel assignments,
182 to measure the effects of ablative fractional CO₂ laser on HTS in two anatomically comparable
183 and independent scars per adult participant. The scars selected are randomly allocated to
184 receive either ablative fractional CO₂ laser therapy or standard care. An independent assessor
185 will be blinded to the intervention and the control scar sites. The sample size will be a
186 maximum of 60 patients, who will each have 3 laser treatments over a 12-month treatment
187 period. After laser treatments, all patients will be followed up until 6-months after the 3rd laser
188 treatment. Biopsies will be taken at pre-treatment (visit 1), and 3-weeks (visit 2), 6-months
189 (visit 4) and 12-months post 1st laser treatment (visit 5); and subsequently assessed for the
190 proportion of senescent cells and fibroblast subsets in the scars. Scar assessments will be
191 performed at specified time points, including pre-laser treatment (visit 1), during laser
192 treatment and post laser treatment (visit 3, 4, 5) to record the scar properties and the
193 psychometric outcomes. Moreover, the study will also collect serum and plasma samples to
194 assess the cellular and molecular biomarkers in response to laser therapy. **Fig 1** outlines the
195 SPIRIT schedule of enrolment, intervention, and data collection. A diagrammatic overview of
196 the SMOOTH trial study design is shown in **Fig 2**. SPIRIT reporting guidelines (28) were used
197 throughout this study (**S1 File**).

198 **Fig 1. SPIRIT schedule of enrolment, interventions, and data collection**

199 **Fig 2. Diagrammatic overview of SMOOTH trial study design**

200 **Study setting**

201 The study will be set in two UK-based hospitals: University Hospital Birmingham and The
202 Welsh Centre for Burns and Plastic Surgery, Morriston Hospital, Swansea, UK.

203 **Study population**

204 SMOOTH is a prospective study and following recommendations for pilot studies,(29) 30
205 patients or more are required to gain estimates of the parameters needed for sample size
206 estimation. We have allowed for a 20% drop-out and possible loss to follow-up and therefore
207 a total of 60 adult participants will be recruited to the study over a 2-year period. This will also
208 allow the recruitment and retention rates to be estimated with 95% confidence interval
209 maximum widths of 20% and 25% respectively. We aim to recruit both civilian and military
210 veterans for this study. Civilian patients will be recruited from the Advanced Scar Management
211 clinic at University Hospital Birmingham and The Welsh Centre for Burns and Plastic Surgery,
212 Morriston Hospital, Swansea. Veterans will be recruited in collaboration with the CASEVAC
213 Club volunteers. Participants will be identified by research clinicians or referred to the burns
214 research team for screening by their primary clinician. Participants will be screened for study
215 eligibility using the following recruitment criteria.

216 **Eligibility criteria**

217 The main inclusion criteria are adult patients aged ≥ 16 years with symptomatic HTS as a result
218 of deep dermal or full thickness burns or trauma that were sustained more than 12 months
219 previously. Patients should have had no previous laser therapy treatment to the study site and
220 the treatment area must be $\geq 25\text{cm}^2$ of confluent scarring with a comparable control scar on
221 the limb or trunk.

222 Patients with concurrent use of pressure garments, emollient application and scar massage
223 will also be included in the study. However, if the patient has recent or concurrent invasive
224 scar treatments, including intralesional pharmaceuticals, micro-needling or other laser
225 modalities (e.g. pulse-dye) on the study site, they will be excluded. Patients with known allergy

226 or contraindication to eutectic mixture of local anaesthesia (ELMA) cream (lidocaine 2.5% and
227 prilocaine 2.5%), components of moisturising cream (benzalkonium chloride 0.1%;
228 chlorhexidine dihydrochloride 0.1%; liquid paraffin 2.5%; isopropyl myristate 2.5%) or ointment
229 (white soft paraffin liquid paraffin %w/w 50/50); and patients with Fitzpatrick skin type of 5-6
230 due to nature of the skin will also be excluded from the study. The main recruitment criteria
231 can be seen in **Fig 3**.

232 **Fig 3. Main recruitment criteria**

233 **Identifying participants and enrolment**

234 Patients will be identified through the Advanced scar management clinic, burns and scar
235 therapist outpatient clinics at QEHB and consultants/therapy led clinics at Morrision Hospital,
236 Swansea. Patients who are deemed suitable will be approached in person by a member of
237 the research team or via telephone during which a brief explanation of the trial will be given. If
238 the patient agreed, a Patient Information Leaflet (PIL) will be sent by mail or given to the patient
239 (**S2 File**).

240 **Consent and withdrawal from study**

241 Written informed consent will be obtained from all participants before the start of the study.
242 The research team will assess patient's eligibility for each treatment intervention, i.e., first,
243 second and third laser treatment, and re-confirm patient's consent to continue with the
244 treatment at each time point.

245 Participants may withdraw or be withdrawn from the study at any time if an incident occurs
246 that renders the participant unable to continue with the study. For example: (1) patients unable
247 to complete all laser therapy sessions as planned; (2) adverse reaction to laser therapy and
248 (3) pregnancy. The reason for discontinuation will be collected and recorded in the electronic
249 case report form. Any data collected at the time of withdrawal may still be included in the data

250 analysis, unless the participant specifically withdraws their consent. Participants will be asked
251 to clarify this at the point of withdrawal.

252 **Randomisation and blinding**

253 Each participant will have their own control scar in an anatomically comparable site either on
254 the trunk or limbs. Allocation of scar treatment will be performed using a computer-based
255 randomisation system developed at the University Hospitals Birmingham NHS Foundation
256 Trust (UHBFT). Two comparable anatomically scarred areas $\geq 25\text{cm}^2$ on trunk, arms or legs
257 will be identified on the same participant and will be described as Scar-A and Scar-B on the
258 body map. The participants' identified scar sites, A and B, will be randomised on a 1:1 basis
259 to either the standard of care or laser treatment as shown in **Fig 4**.

260 **Fig 4. Options of assignment of study areas**

261 **Study schematic**

262 This study is a prospective intra-patient single-blinded randomised controlled pilot study
263 designed to examine the mechanistic basis of ablative fractional CO₂ laser therapy in
264 hypertrophic scarring (**Fig 3**). Patients fulfilling the recruitment criteria will be enrolled into the
265 study. During the pre-assessment visit D0 (visit 1), serum, plasma and three biopsies from
266 one normal control area, and two scar sites (control and intervention) will be obtained. Scar
267 assessments including modified VSS (mVSS), POSAS, BBSIP and European quality of life
268 five dimension (EQ-5D) and objective scar assessments including 3D-Vectra H1 Photography,
269 DermaScan®, Cutometer® and DSMIII ColoriMeter® will also be performed and recorded. The
270 scars will then be randomised after pre-assessment visit using a computer-based
271 randomisation system developed at the UHBFT.

272 During the treatment and assessment visits, patients will receive three laser treatments and
273 time points will occur at 3 months intervals post-recruitment D1 (visit 2), M3 (± 30 days; visit 4)
274 and M6 (± 30 days; visit 5). Prior to each laser treatment schedules, there will be assessment

275 visits where serum, plasma and biopsy samples are collected. The serum and plasma will be
276 collected at all three assessment visits (visit 3, 4 & 5). The biopsies from the treatment site of
277 the scar will be collected at 1st and 3rd assessment visits (visit 3 & 5). Scar assessments will
278 also be performed and recorded during 2nd and 3rd assessment visits (visit 4 & 5). After 3
279 sessions of laser treatment schedule, there will be a follow-up visit 1 year post the 1st laser
280 treatment (visit 6). During this visit, scar assessments will be performed; serum, plasma and
281 biopsies from control and treatment sites will be collected (**Fig 5**).

282 **Fig 5. Overview of SMOOTH study schematic**

283 **Biological measurements**

284 5mm skin punch biopsies will be collected under local anaesthesia from each patient. Three
285 different types of biopsies will be collected at various time points: (1) Normal skin biopsy: pre-
286 assessment visit (visit 1); (2) Control, scar without laser treatment: pre-assessment and follow-
287 up visit (visit 1 & 6); and (3) Intervention, scar with laser treatment: pre-, 1st-, 3rd-assessments
288 and follow-up visit (visit 1, 3, 5 & 6). All biopsies collected from patients will be processed
289 immediately and bisected with one half transferred to a fixative solution (10% neutral buffered
290 formalin) for downstream histological and immunohistochemical assessments. From
291 histological assessment, dermal and epidermal thickness, collagen structure and orientation,
292 elastin density and structure will be recorded, and from immunohistochemical assessments,
293 the proportion of p16INK4A^{+ve} and γ H2AX^{+ve} senescent cells, and fibroblast subpopulations
294 will be measured to investigate variables of scar behaviour in response to laser therapy. The
295 other half of the biopsy will be frozen in CryoStor[®] cell cryopreservation media (Merck Life
296 Science UK Limited, Dorset, UK) and stored at -80°C for future analysis using single cell RNA
297 sequencing (scRNAseq) to delineate the full profile of skin cells present during scar reduction
298 process in response to laser therapy.

299 Serum and plasma will be collected on pre-, 1st-, 2nd- and 3rd- assessment visits (visit 1, 3, 4 &
300 5) and follow-up visit (visit 6). Full white blood cell count will be recorded using Sysmex XN-

301 1000 haematology analyser (Sysmex UK, Milton Keynes, UK). Serum cytokine patterns will
302 be determined using Luminex Assay and a range of pro- and anti-inflammatory cytokines (IL1 β ,
303 IL4, IL6, IL8, IL10, IL13, IL1R α) measured. Other factors measured will include those known
304 to influence scarring, such as TGF β , decorin, PDGF-AA and adiponectin. Double-spun plasma
305 will also be prepared(30) for future analysis of the role of extracellular vesicles and their cargo
306 in scar reduction.

307 **Scar assessments**

308 Scar assessments for both treated and control scars will be performed and recorded, prior to
309 randomisation and before each laser treatment (visit 1, 4, 5 &6). The control scar will be treated
310 as per standard of care, however if the study participant desires laser therapy to the area, this
311 would be done at the 6-month follow-up after study completion. All study visits are aligned with
312 standard of care treatments and no additional follow-up visits would be expected.

313 To associate the findings of the biological measurements with the clinical outcomes, the study
314 will incorporate qualitative and quantitative scar assessments to record scar properties and
315 psychometric outcomes to reflect the clinical effects after laser therapy. Patient reported
316 outcome data will be recorded using a series of patient reported outcome measures (PROMs)
317 and scar assessments. Scars will be assessed using tools including mVSS, POSAS and
318 BBSIP. Scars will also be objectively assessed using 3D-Vectra Photography for scar site
319 identification, DermaScan[®] for scar thickness and density, Cutometer[®] for elasticity and colour
320 using DSMIII Colorimeter[®]. As part of the evaluation of the impact of laser treatment on
321 patients' QoL and the patient reported outcome strategy,(31) a PROMS validation study using
322 Rasch analysis will be carried out to evaluate if the PROMs are useful measurement tools for
323 evaluating the impact of laser therapy on scar tissue and QoL.(32)

324 Scar assessments tools including POSAS and mVSS will be performed by an independent
325 and experienced assessor in scar management and treatment. The health care professional
326 or scar assessor, in addition to the data analysts, will be blinded to the anatomical site (treated

327 scar) receiving laser treatment compared to the non-laser treated scar (control scar). Scar
328 assessment questionnaires, including BBSIP, POSAS, as well as QoL questionnaire EQ-5D
329 will be completed unblinded by participants.

330 All study visits are aligned with standard of care treatments and no additional follow-up visits
331 would be expected. The full trial schema can be seen in **Fig 5**.

332 **Trial intervention**

333 The treatment area is $\geq 25\text{cm}^2$ confluent scarring with an anatomically comparable control scar
334 on the limb or trunk.

335 **Control Area (Standard of Care)**

336 Patients with HTS usually undergo massage therapy, pressure garment application and/or
337 steroid or fluorouracil injection as part of standard practice. The control scar, if deemed of
338 inferior quality to the laser treated area, will be treated as part of the patient routine ongoing
339 management of their scars after the trial is completed.

340 **Treatment Area (Intervention)**

341 The laser treatment will be performed under local anaesthetic and will be conducted by a
342 suitably trained medically qualified doctor. The treatment will use a Lumenis® UltraPulse® CO₂
343 laser device with the DeepFX™ and/or SCAARFX™ headpiece depending on scar thickness
344 assessed by ultrasound prior to treatment. The proposed treatment area will be marked and
345 photo documented. The treatment will include a single pass of the chosen treatment site with
346 the following settings: SCAARFX™: Energy 110-150mJ; Density 3%; Shape: setting 2; Size:
347 setting 10; Pulses 1; and DeepFX™: Energy 17.5-20.0mJ; Density 5%; Shape: setting 2; Size:
348 setting 10; Pulses 1. Repeat rate 0.5 seconds; Frequency 300Hz; No active cooling will be
349 used during the treatment.

350 Laser treatment during the trial will only be carried out on the scar allocated to receive laser
351 treatment. If laser treatment will be done on additional areas, then the scar allocated to receive
352 laser treatment and the same additional site and size will need to be treated based on the time
353 points mentioned in this protocol throughout the study period. This is to ensure that the patient
354 receives the same dose of laser treatment for consistency of assessment throughout the study.

355 **Concomitant therapy**

356 Control and laser treated (randomised) scars, when healed, will be treated as per standard of
357 care which would include silicone, massage and pressure therapy, when applicable.

358 **Study objectives**

359 The study's primary objective is to assess the kinetics of the response to ablative fractional
360 CO₂ laser therapy in HTSs with respect to the cell types present in the treated skin. We will
361 examine the presence of p16INK4A^{+ve} and γH2AX^{+ve} senescent cells, and CD90/Thy1⁺- and
362 αSMA⁺-fibroblast subpopulations together with the combined subjective and objective scar
363 assessments to measure the association between induction of senescent cells and scar
364 reduction after laser treatment.

365 **Outcome measures**

366 During the study, parameters including histological examination of scars following laser
367 therapy will be measured. In addition, treatment outcomes, including both subjective scar
368 assessments (POSAS and mVSS) and objective scar assessments (scar thickness, density,
369 pliability, and colour) will be recorded. Patient reported outcomes will also be measured using
370 BBSIP. Outcome data will be collected at pre-laser, 3 weeks-, 6 months- and 1 year- post the
371 1st laser treatment.

372 Our primary outcome measure is to assess the proportional changes of senescent cells in skin
373 and the changes of sub-populations of fibroblasts using cell markers αSMA and CD90/Thy1

374 in HTS after laser therapy via immunohistochemical staining. Secondary outcome measures
375 comprise a range of scar assessment tools, including mVSS, POSAS, BBSIP and EQ-5D
376 generic health status assessments. Scars will also be assessed through histological
377 examinations to assess dermal and epidermal thickness, collagen structure and orientation,
378 elastin density and structure following treatments.

379 Exploratory measures for novel markers associated with scarring and tissue regenerative
380 capabilities such as extracellular vesicle associated microRNAs, cytokines, TGF β , decorin,
381 PDGF-AA and adiponectin will also be assessed. As part of the patient reported outcome
382 strategy, we will evaluate the extent to which the PROMs are sound psychometric measures
383 of improvements in scarring using Rasch analysis, and the impact on participant's QoL as a
384 result of laser treatment. So as not to miss any novel cells that may be induced, we will also
385 use scRNAseq to fully characterise cells present in the laser treated tissue. This technique
386 has been used previously to identify the role of Engrailed-expressing fibroblasts in the scarring
387 process in mice.(33) This technique will also allow us to determine the transcriptomic response
388 to therapy to further define the mediators of the beneficial effects of laser therapy.

389 **Data Management**

390 **Data analysis plan**

391 Following recommendations for pilot studies, 30 patients or more are typically required to gain
392 estimates of the parameters needed for sample size estimation. No formal sample size
393 calculation has been performed as a result. We have allowed for a 20% drop-out and possible
394 loss to follow-up. We therefore aim to recruit 60 patients in total. This will also allow the
395 recruitment and retention rates to be estimated with 95% confidence interval maximum widths
396 of 20% and 25% respectively.

397 All analysis will be based on the intention to treatment principle. The primary comparison
398 groups will be the scar sections randomised to standard of care (control group) versus those

399 randomised to treatment with laser therapy (experimental group). The data analysis for this
400 pilot study will be descriptive and mainly focus on confidence interval estimation, with no
401 formal hypothesis testing performed. Dichotomous feasibility measures, such as the
402 recruitment and retention rates, including completeness of data will be reported as numbers
403 and percentages. These values will be summarised across participants or treatment groups
404 as appropriate.

405 Analysis methods will be chosen according to the data type: 1. Continuous endpoints (e.g.
406 mVSS total score): These data will be summarised using means and standard deviations, with
407 differences in means with 95% confidence intervals reported. Longitudinal plots of the data
408 over time will also be constructed for visual presentation of the data. 2. Categorical
409 (dichotomous) endpoints (e.g. rates of improvement in scar domains): the number and
410 percentages of participants/scars experiencing the event will be summarised across and
411 between groups. For exploratory outcome data about the biomarkers of the scar response to
412 laser therapy, the various cellular and molecular variables will be examined for relationships
413 to scarring using logistic regression.

414 **Data management**

415 The data collection tool for this study will be both paper and electronic CRFs. The data
416 collection may be conducted by the CRN nurses, the PIs, the health care professionals or the
417 research fellows involved in the study. Collected data will be entered electronically onto the
418 online trial database, REDCap Cloud. The database REDCap cloud is run by the Birmingham
419 Surgical Trials Consortium (BiSTC), University of Birmingham, under licence from Vanderbilt
420 University. Primary analysis for the trial will occur once all participants have completed the 12-
421 month assessment and corresponding outcome data has been entered onto the trial database,
422 validated as being ready for analysis, and the database locked. This analysis will include data
423 items up to and including the 12-month assessment.

424 **Data monitoring**

425 All data collected will be recorded and stored in the trial site file, including the original signed
426 informed consent form (**S3 File**), will be stored in the recruitment sites for quality control
427 purposes. Patient's confidentiality will be maintained and follow the General Data Protection
428 Regulation guidelines at all times and data will not be disclosed without written consent.
429 Principal investigator will be responsible for the secure storage of all trial related
430 documentation. All documentation including copies of protocols, patient's information leaflets,
431 GP letters, consent forms, and CRFs will be held securely in accordance with current ICH
432 GCP guidelines for a minimum of fifteen years. The records will be available for review by
433 governing bodies upon request following notice. All trial documents will be archived in
434 accordance with the UHBFT Archiving Procedures.

435 **Patient and public involvement**

436 UHB's Accident, Burns and Critical Care (ABC) PPI group have been involved in the
437 development stage of the proposed study up to the finalisation of the study protocol and study
438 documents.

439 **Ethics and dissemination**

440 The SMOOTH Study is conducted according to the Declaration of Helsinki (2008). It received
441 favourable opinion on from the North Scotland Research Ethics Committee (REC reference:
442 19/NS/0125). Consequently, on 22nd September 2022, the Health Research Authority (HRA)
443 and Health and Care Research Wales (HCRW) issued the approval. This article refers to
444 protocol v.7.0 dated 22nd September 2022 (**S4 File**). Results will be disseminated via peer-
445 reviewed publication and presentations at national and international conferences.

446 **Status and timeline of the study**

447 The SMOOTH study is an ongoing trial with an estimated finishing time by the end of August
448 2023.

449 **Trial registration:** ClinicalTrials.gov: NCT04736251. Trial registration dataset: **S1 Table**.

450 **Discussion**

451 Hypertrophic scarring is one of the major concerns after burn injury, with detrimental physical
452 and psychological consequences. Despite laser therapy has been used for treating HTS for
453 some time with various positive outcomes, the mechanism of actions remains not fully
454 understood. In this study, we used a longitudinal study design to enable us delineating the
455 cellular kinetics within the hypertrophic scars after laser treatment. In order to help us to limit
456 the variations due to physiological differences from different anatomical sites, we applied an
457 intra-participant randomisation type 1:1 control and treatment comparable area in the same
458 participant. Furthermore, to represent a more thorough and reliable overall clinical outcome,
459 we incorporate both objective scar assessment tools with subjective scoring systems to
460 evaluate treatment outcomes. With this study protocol, we believe it will provide us an
461 improved understanding of mechanisms mediating scar reduction with laser treatment, which
462 will enable better design of laser treatment regimens, and thus benefit those living with HTS.

463 **Roles and responsibilities**

464 **Sponsor contact information**

465 University Hospital Birmingham Foundation Trust. Mindelsohn Way, Edgbaston, Birmingham,
466 B15 2WB.

467 **Funder information**

468 This work is supported by the Chancellor using LIBOR funds via a grant obtained by The Scar
469 Free Foundation.

470 **Authors' contributions**

471 NSM is the chief investigator and was responsible for the design and development of the
472 SMOOTH study. JML, YW and JY are principal investigators that assisted in protocol
473 development and/or design. JB, AS, YYC, KMP and TH assisted in protocol design. YYC,
474 KMP, RI, TH, EA, AA and MV commented on the protocol and are involved in the acquisition
475 of data. YYC, KMP and RI wrote the manuscript and all authors revised and approved the final
476 version.

477 **Sponsor and funder statement**

478 The funding source will have no role or authority over study design, data collection,
479 management, analysis, interpretation of the data or writing of the report; neither will the source
480 have decision to submit report for publication.

481 **Competing interests statement**

482 No competing interests declared

483 **Acknowledgement**

484 This project is funded by the Scar Free Foundation. The authors would like to thank the SFF,
485 University Hospital Birmingham Foundation Trust, National Institute for Health and Care
486 Research, the UHB's Accident, Burns and Critical Care (ABC) PPI group and the patients
487 involved in this study.

488 **Supporting information**

489 **S1 File. SPIRIT checklist**

490 **S2 File. Modelled SMOOTH patient information leaflet v7.0**

491 **S3 File. Modelled SMOOTH informed consent form**

492 **S4 File. SMOOTH protocol version 7**

493 **S1 Table. Trial registration dataset**

494 **References**

- 495 1. Organisation WH. Fact Sheet, Burns 2018 [[https://www.who.int/en/news-room/fact-](https://www.who.int/en/news-room/fact-sheets/detail/burns)
496 [sheets/detail/burns](https://www.who.int/en/news-room/fact-sheets/detail/burns)].
- 497 2. Guest JF, Fuller GW, Edwards J. Cohort study evaluating management of burns in the
498 community in clinical practice in the UK: costs and outcomes. *BMJ Open*. 2020;10(4):e035345.
- 499 3. Jeschke MG, van Baar ME, Choudhry MA, Chung KK, Gibran NS, Logsetty S. Burn injury. *Nat*
500 *Rev Dis Primers*. 2020;6(1):11.
- 501 4. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids:
502 pathomechanisms and current and emerging treatment strategies. *Mol Med*. 2011;17(1-2):113-25.
- 503 5. Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic
504 scarring: the greatest unmet challenge after burn injury. *Lancet*. 2016;388(10052):1427-36.
- 505 6. Gangemi EN, Gregori D, Berchialla P, Zingarelli E, Cairo M, Bollero D, et al. Epidemiology and
506 risk factors for pathologic scarring after burn wounds. *Arch Facial Plast Surg*. 2008;10(2):93-102.
- 507 7. Liuzzi F, Chadwick S, Shah M. Paediatric post-burn scar management in the UK: a national
508 survey. *Burns*. 2015;41(2):252-6.
- 509 8. Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. *Am Fam*
510 *Physician*. 2009;80(3):253-60.
- 511 9. Trislina Perdanasari A, Lazzeri D, Su W, Xi W, Zheng Z, Ke L, et al. Recent developments in the
512 use of intralesional injections keloid treatment. *Arch Plast Surg*. 2014;41(6):620-9.
- 513 10. Friedstat JS, Hultman CS. Hypertrophic burn scar management: what does the evidence show?
514 A systematic review of randomized controlled trials. *Ann Plast Surg*. 2014;72(6):S198-201.
- 515 11. Safer LF, Wood CE. The argon laser for cutaneous lesions. *JAMA*. 1982;247(1):29.
- 516 12. Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. *Plast Reconstr Surg*.
517 1998;102(6):2190-5.

- 518 13. Asilian A, Salimi E, Faghihi G, Dehghani F, Tajmirriahi N, Hosseini SM. Comparison of Q-
519 Switched 1064-nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial
520 acne scar. *J Res Med Sci*. 2011;16(9):1189-95.
- 521 14. Allison KP, Kiernan MN, Waters RA, Clement RM. Pulsed dye laser treatment of burn scars.
522 Alleviation or irritation? *Burns*. 2003;29(3):207-13.
- 523 15. Zuccaro J, Ziolkowski N, Fish J. A Systematic Review of the Effectiveness of Laser Therapy for
524 Hypertrophic Burn Scars. *Clin Plast Surg*. 2017;44(4):767-79.
- 525 16. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new
526 concept for cutaneous remodeling using microscopic patterns of thermal injury. *Lasers Surg Med*.
527 2004;34(5):426-38.
- 528 17. Ramsdell WM. Fractional carbon dioxide laser resurfacing. *Semin Plast Surg*. 2012;26(3):125-
529 30.
- 530 18. Preissig J, Hamilton K, Markus R. Current Laser Resurfacing Technologies: A Review that Delves
531 Beneath the Surface. *Semin Plast Surg*. 2012;26(3):109-16.
- 532 19. Ross EV, McKinlay JR, Anderson RR. Why does carbon dioxide resurfacing work? A review.
533 *Arch Dermatol*. 1999;135(4):444-54.
- 534 20. Fu X, Dong J, Wang S, Yan M, Yao M. Advances in the treatment of traumatic scars with laser,
535 intense pulsed light, radiofrequency, and ultrasound. *Burns Trauma*. 2019;7:1.
- 536 21. Karmisholt KE, Banzhaf CA, Glud M, Yeung K, Paasch U, Nast A, et al. Laser treatments in early
537 wound healing improve scar appearance: a randomized split-wound trial with nonablative fractional
538 laser exposures vs. untreated controls. *Br J Dermatol*. 2018;179(6):1307-14.
- 539 22. Lee KC, Dretzke J, Grover L, Logan A, Moiemmen N. A systematic review of objective burn scar
540 measurements. *Burns Trauma*. 2016;4:14.
- 541 23. Lee KC, Bamford A, Gardiner F, Agovino A, Ter Horst B, Bishop J, et al. Investigating the intra-
542 and inter-rater reliability of a panel of subjective and objective burn scar measurement tools. *Burns*.
543 2019;45(6):1311-24.

- 544 24. Darby IA, Laverdet B, Bonte F, Desmouliere A. Fibroblasts and myofibroblasts in wound healing.
545 Clin Cosmet Investig Dermatol. 2014;7:301-11.
- 546 25. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell.
547 2013;153(6):1194-217.
- 548 26. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role
549 for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell. 2014;31(6):722-
550 33.
- 551 27. Terlecki-Zaniewicz L, Pils V, Bobbili MR, Lammermann I, Perrotta I, Grillenberger T, et al.
552 Extracellular Vesicles in Human Skin: Cross-Talk from Senescent Fibroblasts to Keratinocytes by
553 miRNAs. J Invest Dermatol. 2019;139(12):2425-36 e5.
- 554 28. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
555 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
- 556 29. Browne RH. On the use of a pilot sample for sample size determination. Stat Med.
557 1995;14(17):1933-40.
- 558 30. Coumans FAW, Brisson AR, Buzas EI, Dignat-George F, Drees EEE, El-Andaloussi S, et al.
559 Methodological Guidelines to Study Extracellular Vesicles. Circ Res. 2017;120(10):1632-48.
- 560 31. Retzer A, Aiyegbusi OL, Rowe A, Newsome PN, Douglas-Pugh J, Khan S, et al. The value of
561 patient-reported outcomes in early-phase clinical trials. Nat Med. 2022;28(1):18-20.
- 562 32. Browne JP, Cano SJ. A Rasch Measurement Theory Approach to Improve the Interpretation of
563 Patient-reported Outcomes. Med Care. 2019;57 Suppl 5 Suppl 1:S18-S23.
- 564 33. Tabib T, Morse C, Wang T, Chen W, Lafyatis R. SFRP2/DPP4 and FMO1/LSP1 Define Major
565 Fibroblast Populations in Human Skin. J Invest Dermatol. 2018;138(4):802-10.

566

Study Schedule	Visit 1 Recruitment ¹⁰ Pre-Assessment ¹¹ (Day 0)	Visit 2 1 st treatment ¹² (Day 1)	Visit 3 3 weeks ¹³ Post 1 st treatment (Day 22 ± 3 days)	Visit 4 2 nd Treatment ¹⁴ (Month 3 ± 30 days)	Visit 5 3 rd Treatment ¹⁵ (Month 6 ± 30 days)	Visit 6 1 year post 1 st treatment (Month 12 ± 30 days)
Informed Consent	x					
Inclusion and Exclusion Criteria	x					
Medical History ¹	x					
Adverse Events		x	x	x	x	x
Concomitant Medications	x	x	x	x	x	x
Registration & Randomisation	x					
Screen for pregnancy ²	x	x		x	x	
Burn Assessments						
Record Burn injury details ³						
Record Treatment Site ⁴	x	x	x	x	x	x
Clinical photography ⁵	x		x	x	x	x
Treatment⁶						
Laser Therapy ⁷		x		x	x	
Scar Assessments						
3D Vectra Camera photography	x			x	x	x
Dermascan® ultrasound	x			x	x	x
Cutometer®	x			x	x	x
DSM II colormeter®	x			x	x	x
Modified Vancouver Scar Scale (mVSS)	x			x	x	x
Patient and Observer Scar Assessment Scale (POSAS)	x			x	x	x
Brisbane Bars Scar Impact Profile Score (BBSIP)	x			x	x	x
Quality of Life Questionnaire (EQ-5D)	x			x	x	x
Laboratory Tests						
Blood sample ⁸	x		x	x	x	x
Normal skin biopsy ⁹ (Baseline)	x					
Scar Non-laser treated biopsy ⁹ (Control)	x					x
Scar treated with laser biopsy ⁹ (Randomised)	x		x		x ¹⁶	x

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.19.23288792>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

1. Medical History - include patient demographics e.g. age, gender, ethnicity, medical co-morbidities including psychiatric or behavioural problems and history of alcohol or substance misuse
2. Screen for pregnancy - pregnancy test not routinely performed unless suspected.
3. Record Burn injury details - include % Total Body Surface Area (TBSA) Burned or surface area traumatised (calculated by Lund & Browder Chart), Burn/trauma mechanism e.g. flame, scald etc
4. Record Treatment site - Anatomical location of scar to be treated with Laser therapy (wound map)
5. Clinical Photography - of area of interest - randomised/treatment and control areas
6. Treatment - 3 months intervals post recruitment (±30 days)
7. Laser Therapy - use a Lumenis® UltraPulse® CO₂ laser device with the SCAARFX™. Energy 110-150 mJ; Density 3%; Shape: setting 2; Size: setting 10; Pulses 1; and DeepFX™ Energy 17.5-20.0 mJ; Density 5%; Shape: setting 2; Size: setting 10; Pulses 1; Repeat rate 0.5 - 1 seconds; Frequency 250 - 300Hz; No active cooling will be used during the treatment
8. Bloods - x1 sodium citrate tube and x1 serum tube
9. Biopsy - 5mm punch biopsy
10. Recruitment - Day 0 of study
11. Pre Laser Assessment - Baseline assessment prior to first laser treatment
12. 1st Treatment - Day 1 - Day of first laser intervention
13. 3 weeks post treatment Assessment - ±3days allowance
14. 2nd Treatment - Month 3 - Laser treatment at 3 months ±30days after the 1st treatment
15. 3rd Treatment - Month 6 - Laser treatment at 6 months ±30days after the 1st treatment
16. Third Treatment Visit - 5mm punch biopsy to be performed, i.e., before the third laser therapy




Fig 2

BOX 1 Main Recruitment Criteria

General inclusion criteria

- Adult patients ≥ 16 years of age
- Patient with symptomatic hypertrophic scarring as a result of deep dermal or full thickness burns or trauma
- Burn or trauma sustained more than 12 months prior to recruitment
- Treatment area to be $\geq 25\text{cm}^2$ confluent scarring with a comparable control scar on the limb or trunk.

General exclusion criteria

- Patients under 16 years of age
- Previous laser therapy treatment to the study site
- The use of recent (within 6 months) or concurrent invasive scar treatments, including intralesional pharmaceuticals, micro-needling or other laser modalities (e.g. pulse-dye) on the study site
- Known allergy or contraindication to eutectic mixture of local anaesthesia (EMLA) cream (lidocaine 2.5% and prilocaine 2.5%), components of moisturising cream (benzalkonium chloride 0.1%; chlorhexidine dihydrochloride 0.1%; liquid paraffin 2.5%; isopropyl myristate 2.5%) or ointment (liquid paraffin 50% in white soft paraffin)
- Patients with Fitzpatrick skin type of 5 or 6 due to nature of the skin

Laser treatment exclusion criteria

- The presence of acute infection at the proposed treatment site
- Pregnancy or lactation
- Patients with poorly controlled diabetes mellitus (HbA1C $>9\%$ or 75mmol/mol within last 3 months)
- Patients experiencing acute exacerbation of chronic skin diseases e.g. psoriasis or eczema
- Immunosuppression (HIV, drugs with immunosuppressive effect)
- Use of isotretinoin (Roaccutane) at any time within the last 6 months
- Autoimmune disorders in active stage (for example: 1. Localised: Addison's, Grave's and Crohn's Disease. 2. Systemic: Rheumatoid arthritis, multiple sclerosis, lupus and scleroderma)
- Known history of keloid scarring

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.19.23288792>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Option	Treatment allocation for Scar A	Treatment allocation for Scar B
1	Standard of care	Laser treatment
2	Laser treatment	Standard of care




Fig 4

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.19.23288792>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Fig 5